Perrigo Company plc Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share
Perrigo Company plc (PRGO) reported Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share of -$0.10 per share for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare · last filed 2026-08-05
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2026-06-27 was -$0.10.
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2026-03-28 was -$0.06.
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2025-09-27 was -$0.04.
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2025-06-28 was -$0.06.
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2025 was -$0.17.
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2024 was -$0.08.
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2023 was -$0.06.
- Perrigo Company plc discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2022 was -$0.07, a 115.22% decline from fiscal 2021.
| Period end | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 6 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2026-06-27 | -$0.10 10-Q · filed 2026-08-05 | -$0.16 10-Q · filed 2026-08-05 | ||
| 2026-03-28 | -$0.06 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$0.17 10-K · filed 2026-02-26 | |||
| 2025-09-27 | -$0.04 10-Q · filed 2025-11-05 | -$0.14 10-Q · filed 2025-11-05 | ||
| 2025-06-28 | -$0.06 10-Q · filed 2026-08-05 | -$0.10 10-Q · filed 2026-08-05 | ||
| 2025-03-29 | -$0.05 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$0.08 10-K · filed 2026-02-26 | |||
| 2024-09-28 | -$0.02 10-Q · filed 2025-11-05 | -$0.06 10-Q · filed 2025-11-05 | ||
| 2024-06-29 | -$0.02 10-Q · filed 2025-08-06 | -$0.04 10-Q · filed 2025-08-06 | ||
| 2024-03-30 | -$0.02 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$0.06 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$0.01 10-Q · filed 2024-11-06 | -$0.03 10-Q · filed 2024-11-06 | ||
| 2023-07-01 | $0.00 10-Q · filed 2024-08-02 | -$0.02 10-Q · filed 2024-08-02 | ||
| 2023-04-01 | -$0.01 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$0.07 10-K · filed 2025-02-28 | |||
| 2022-10-01 | $0.02 10-Q · filed 2023-11-07 | $0.01 10-Q · filed 2023-11-07 | ||
| 2022-07-02 | $0.00 10-Q · filed 2023-08-08 | -$0.01 10-Q · filed 2023-08-08 | ||
| 2022-04-02 | -$0.01 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.46 10-K · filed 2024-02-27 | |||
| 2021-10-02 | -$0.04 10-Q · filed 2022-11-08 | $0.63 10-Q · filed 2022-11-08 | ||
| 2021-07-03 | $0.41 10-Q · filed 2022-08-09 | $0.67 10-Q · filed 2022-08-09 | ||
| 2021-04-03 | $0.27 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | -$1.52 10-K · filed 2023-02-28 | |||
| 2020-09-26 | -$1.32 10-Q · filed 2021-11-12 | -$0.62 10-Q · filed 2021-11-12 | ||
| 2020-06-27 | $0.35 10-Q · filed 2021-08-11 | $0.71 10-Q · filed 2021-08-11 | ||
| 2020-03-28 | $0.36 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$0.09 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |